SAN MATEO, CA, EpiBiologics, a leader in tissue-selective extracellular protein degradation, announced the completion of a $107 million Series B financing.
EpiBiologics, a leader in tissue-selective extracellular protein degradation, announced the completion of a $107 million Series B financing co-led by GV (Google Ventures) and Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation- JJDC, Inc (JJDC).
Novartis Venture Fund (NVF), Aulis Capital, Avego BioScience Capital, and Samsara BioCapital joined JJDC as new investors. In addition to GV, existing investors Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital, and Mission BioCapital participated in the round.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
